entertainment -WSS

entertainment

author：knowledge 2025-09-30 18:54:11 - browse：6786

Fiona Marshall, president of the Novartis research hub in Cambridge, Mass., speaks Thursday during the STAT Future Summit. STAT

Swiss drugmaker Novartis’ research and development hub has a new name — and a new guiding strategy.

The hub, which is headquartered in Cambridge, Mass., and for years has been known as Novartis Institutes for BioMedical Research, or NIBR, will soon simply be known as Novartis Biomedical Research.

But that’s not the only thing that’s changing, Fiona Marshall, the hub’s president, told a virtual audience Thursday during the 2023 STAT Future Summit. The new name reflects a larger shift by the pharma giant to retool its research strategy — from one driven by the pure pursuit of scientific discovery to a tighter focus on projects likely to yield commercially successful drugs.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： New guidelines on severe brain injury complicate already difficult decisions

hotspot

WSS

Elon Musk says Twitter has 'negative cash flow' and 'heavy debt'

4 killed in mass shooting in Georgia, shooter remains on the loose: Police

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

Congress: Eradicate hepatitis C and reduce the deficit

Argenx drug significantly slows progression of nerve disorder

4 killed in mass shooting in Georgia, shooter remains on the loose: Police

hotspot

entertainment

focus

Hollywood unions extend contract negotiations for actors

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

Psychedelics group wrestles with new pharma identity

Care demand spikes challenge UnitedHealth’s provider arm

Apple is now the first public company to be valued at $3 trillion

Grail faces three suits alleging harassment, retaliation

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

With FDA staff opposed to Sarepta therapy, top official intervened

Drug repurposing or repositioning? The language matters

Paxlovid study fails to answer questions over benefit for broader groups

explore

The strategy behind pharma's lawsuits over drug pricing reform

Who gets to use the title 'doctor'?

Death of patient in Alzheimer’s trial raises question of possible risks

Does aspartame cause cancer? What new WHO guidance says

Death of patient in Alzheimer’s trial raises question of possible risks

The science behind Janet Jackson's pregnancy at 49

hotspot

hotspot

focus

focus